Tagrisso (Osimertinib )

Tagrisso (Osimertinib) is a targeted therapy specifically designed for patients with non-small cell lung cancer (NSCLC) that harbor specific mutations in the epidermal growth factor receptor (EGFR) gene. This medication is particularly effective for those with the EGFR T790M mutation, which can develop as a resistance mechanism to first-generation EGFR inhibitors.

Some key highlights of Tagrisso include:

• Mechanism of Action: Tagrisso works by inhibiting the activity of mutant EGFR proteins, thus preventing cancer cell growth and proliferation.


• Indications: It is indicated for the treatment of patients with locally advanced or metastatic NSCLC with EGFR mutations, including those who have progressed on or after prior EGFR TKI therapy.


• Clinical Efficacy: Clinical studies have demonstrated significant improvements in progression-free survival compared to older treatments, making it a preferred option for many oncologists.


• Administration: Tagrisso is taken orally, which provides convenience and flexibility for patients compared to intravenous options.


• Side Effects: Common side effects may include diarrhea, rash, and fatigue. However, these are typically manageable and less severe than those associated with traditional chemotherapy.


• Monitoring: Regular monitoring through imaging and assessments is essential to evaluate treatment response and manage any potential adverse effects.


• Patient Support: Many resources and support programs are available for patients taking Tagrisso, including financial assistance and educational materials to help navigate their treatment journey.

Overall, Tagrisso represents a significant advancement in the treatment of EGFR-mutated NSCLC, offering hope and improved outcomes for many patients facing this challenging diagnosis.

• Osimertinib


• Microcrystalline cellulose


• Croscarmellose sodium


• Magnesium stearate


• Film coating


• Polyvinyl alcohol


• Titanium dioxide


• Macrogol


• Iron oxide red


• Iron oxide yellow

Tagrisso (Osimertinib) is a medication used to treat certain types of non-small cell lung cancer (NSCLC) that have specific mutations in the EGFR gene. It is essential to follow the prescribed instructions from your healthcare provider when using this medication.

To use Tagrisso effectively, follow these steps:

1. Consult Your Healthcare Provider: Before starting Tagrisso, discuss your medical history and any current medications with your doctor to ensure it is safe for you.


2. Dosage: Take Tagrisso exactly as prescribed by your healthcare provider. The usual dose is one tablet taken once daily.


3. Administration: Swallow the tablet whole with a glass of water. Do not chew, crush, or split the tablet.


4. Timing: It can be taken with or without food. Try to take it at the same time each day to help remember.


5. Missed Dose: If you miss a dose, take it as soon as you remember on the same day. If it is almost time for your next dose, skip the missed dose and resume your regular schedule. Do not take two doses at once.


6. Storage: Store Tagrisso at room temperature, away from moisture and heat. Keep it out of reach of children.


7. Monitoring: Regular follow-up appointments with your healthcare provider are essential to monitor your progress and manage any side effects.


8. Side Effects: Be aware of potential side effects such as diarrhea, rash, or fatigue. Contact your healthcare provider if you experience severe or persistent symptoms.

Always remember to read the patient information leaflet provided with your medication for detailed information and instructions. If you have any questions or concerns about using Tagrisso, do not hesitate to reach out to your healthcare provider for assistance.